Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L)

The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alteratio...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Mol Oncol
Hoofdauteurs: Sakai, Kazuko, Takahama, Takayuki, Shimokawa, Mototsugu, Azuma, Koichi, Takeda, Masayuki, Kato, Terufumi, Daga, Haruko, Okamoto, Isamu, Akamatsu, Hiroaki, Teraoka, Shunsuke, Ono, Akira, Ohira, Tatsuo, Yokoyama, Toshihide, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko, Nishio, Kazuto
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Research Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782093/
https://ncbi.nlm.nih.gov/pubmed/33131198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12841
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items